Metabasis Therapeutics (MBRX) Announces Research Collaboration Agreement with Roche
More News related to MBRX
- Trading Outlook for Metabasis Therapeutics Issued by StockPreacher.com
- Ligand Pharmaceuticals (LGND) To Acquire Metabasis Therapeutics (MBRX)
- Ligand to Acquire Metabasis for Cash and Contingent Value Rights
- Metabasis Announces Ligand to Acquire Metabasis for Cash and Contingent Value Rights
- Morning Movers 10/09: SCIL, MBRX, CAGC, AVNR, PSTA, SRZ, ELGX Higher; SPPI, ACOR, LXRX Lower
More News related to FDA
- Kensey Nash (KNSY) Receives FDA Clearance for its First Extracellular Matrix Product, Medeor
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced today that it has entered into a two-year research collaboration agreement with Roche to apply Metabasis’ HepDirect liver-targeting technology to Roche’s proprietary lead nucleosides in order to develop new treatments for hepatitis C virus (HCV).
Under the terms of the agreement, Roche will provide a $10 million upfront payment. In the event a development candidate is identified, Roche will assume development responsibility, and Metabasis will be eligible to receive up to $193 million in additional payments upon achievement of predetermined preclinical and clinical development events, as well as regulatory and commercialization events for each product. For any marketed products that result from the collaboration, Roche will retain full commercial rights and pay Metabasis a royalty on net sales.
Related Categories
FDAHot List
Momentum Movers
Stocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
